The goal of a recent study published in the Chinese Journal of Contemporary Pediatrics was toexplore the intervention measures used to maintain clinical control in children with asthma in the remission stage, when concomitant with acute upper respiratory infection (AURI). This study identified 100 asthmatic children who had achieved clinical control. Participants were randomly divided into an observation group and a control group; both groups were treated with a combination of inhaled corticosteroids and long-acting beta-2 receptor agonist (ICS/LABA) at the lowest dose every night. Conventional therapies were used for the two groups when suffering from AURI. The observation group also received an early short-term upgrade therapy as maintenance therapy – the same amount of ICS/LABA complex preparation was inhaled every morning which lasted for 7-10 days. Both groups were treated following the asthma guidelines, according to disease severity at the time of acute attacks. The asthma control rate, severity of acute attacks, changes in pulmonary function indices and occurrence of adverse events were evaluated after 3, 6, 9 and 12 months of treatment. It was observed that at each time point during follow-up, the rate of asthma control in the observation group was markedly higher than that in the control group. While the severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points. Furthermore, compared to the control group, the observation group had notably improved pulmonary function indices of large and small airways and considerably reduced meandoses of inhaled glucocorticoids and impact on quality life. From the results, it was inferred that an early short-term upgrade therapy for children with asthma in the remission stage, when concomitant with AURI, can prevent acute attacks of asthma, raise theasthma control rate and improve pulmonary function.